

Kesarwani A, Yadav AK, Singh S, Gautam H, Singh HN, Sharma A, Yadav C. Theoretical aspects of transdermal drug delivery system. *Bull. Pharm. Res.* 2013;3(2):78-89.

References (36):

1. Al-Khamis KI, Davis SS, Hadgraft J. Microviscosity and drug release from topical gel formulations. *Pharm. Res.* 1986;3(4):214-7. [DOI: 10.1023/A:1016386613239]
<http://link.springer.com/article/10.1023%2FA%3A1016386613239>
2. Allen, Jr LV, Popovich NG, Ansel HC. Pharmaceutical dosage forms and drug delivery systems. Wolters Kluwer Publishers, New Delhi: 2001; 298-9.
3. Anon. Transdermal delivery systems-general drug release standards. *Pharmacopeial Forum.* 1980;14:3860-5.
4. Banker GS, Rhodes CT. Modern pharmaceuticals. 2nd edition, Marcel Dekkar, Inc., New York: 1990; 239-299.
http://books.google.co.in/books?id=6xVtAAAAMAAJ&source=gbs_book_other_versions
5. Bharkatiya M, Nema RK, Bhatnagar M. Designing and characterization of drug free patches for transdermal application. *Int. J. Pharm. Sci. Drug Res.* 2010;2(1):35-9.
<http://www.ijpsdr.com/pdf/vol2-issue1/6.pdf>
6. Bhatt S, Ramana MV, Pathak K. Fabrication and evaluation of polymeric films for transdermal delivery of metoprolol tartarate. *Egypt. Pharm. J.* 2006;5(1):19-28.
<http://derp.sti.sci.eg/details.aspx?Id=Egyptian%20Pharmaceutical%20Journal%20%28NR%29%20%28Print%29>
7. Chien YW. Novel drug delivery systems. Marcel Dekkar, New York: 1992; 50, 797.
http://books.google.co.in/books/about/Novel_Drug_Delivery_Systems.html?id=HBH-0KaFWDkC&redir_esc=y
8. Crawford RR and Esmerian OK. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. *J. Pharm. Sci.* 1971;60(2):312-4.
<http://onlinelibrary.wiley.com/doi/10.1002/jps.2600600238/abstract>
9. Darwhekar G, Jain DK, Patidar VK. Formulation and evaluation of transdermal drug delivery system of clopidogrel bisulfate. *Asian J. Pharm. Life Sci.* 2011;1(3):269-78.
www.ajpls.com/admin/Issues/Plssue110.pdf
10. Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based transdermal delivery of levonorgestrel. *J. Biomater. Appl.* 1997;12(1):77-88.
<http://www.ncbi.nlm.nih.gov/pubmed/9285331>

11. Dubey S. Laser microporation for the delivery of drugs into and across the skin. *Bull. Pharm. Res.* 2012;2(3):118-23.
<http://www.appconnect.in/wp-content/uploads/2011/03/ReprintBPR055.pdf>
12. Guy RH. Current status and future prospects of transdermal drug delivery. *Pharm. Res.* 1996; 13(12):1765-9. [DOI: 10.1023/A:1016060403438]
<http://link.springer.com/article/10.1023/A%3A1016060403438>
13. Hadgraft J, Guy RH. Transdermal Drug Delivery: Developmental Issues and Research Initiatives. Marcel Dekker, Inc.: New York, 1989; 293-311.
http://books.google.co.in/books/about/Transdermal_drug_delivery.html?id=wQhtAAAAMAAJ&redir_esc=y
14. Jain NK. Advance in controlled and novel drug delivery. CBS Publishers and Distributors, New Delhi: 2001; 108-10.
15. Keleb E, Sharma RK, Mosa EB and Aljahwi AZ. Transdermal drug delivery system - Design and evaluation. *Int. J. Adv. Pharm. Sci.* 2010;1(3):201-11.
<http://www.arjournals.org/index.php/ijaps/article/view/171>
16. Khan IN, Khan MI, Mazumder K, Ajrin M, Sen N, Rashid A, Bhuiya AM. Characterization and *ex-vivo* skin permeation study of domperidone maleate transdermal patch. *Bull. Pharm. Res.* 2012;2(1):15-21.
<http://www.appconnect.in/wp-content/uploads/2013/06/ReprintBPR037.pdf>
17. Latheeshlal L, Phanitejaswini P, Soujanya Y, Swapna U, Sarika V, Moulika G. Transdermal drug delivery systems: an overview. *Int. J. PharmTech Res.* 2011;3(4):2140-8.
http://sphinxesai.com/Vol.3No.4/pharm/Vol.3No.4_pharm4.htm
18. Mayorga P, Puisieux F, Couarraze G. Formulation study of a transdermal delivery system of primaquine. *Int. J. pharm.* 1996;132(1-2):71-9.
<http://www.sciencedirect.com/science/article/pii/0378517395043489>
19. Mohabe V, Akhand R, Pathak AK. Preparation and evaluation of captopril transdermal patches. *Bull. Pharm. Res.* 2011;1(2):47-52.
www.appconnect.in/wp-content/uploads/2012/01/Reprint-BPR022.pdf
20. Naik A, Pechtold LARM, Potts RO, Guy RH. Mechanism of oleic acid-induced skin penetration enhancement *in vivo* in humans. *J. Control. Rel.* 1995;37(3):299-306.
<http://www.sciencedirect.com/science/article/pii/0168365995000887>
21. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review. *The Pharm. Innov.* 2012;1(4):78-87.
<http://www.thepharmajournal.com/vol1Issue4/8.html>

22. Pathak K, Dahiya S, Pathak D, Dahiya R. Electrically assisted drug delivery. *The Indian Pharmacist* 2006;5(47):27-30.
<http://cat.inist.fr/?aModele=afficheN&cpsidt=18872729>
23. Robinson JR, Yang X. Absorption enhancers. In: Swarbrick J, Boylan J (editors), *Encyclopedia of Pharmaceutical Technology*, Vol. 18, Marcel Dekker: New York, 1999; 1-20.
24. Schofield OMV, Rees JL. Skin disease, In Hunter J (editor), *Devidsin's Principle and Practices of Medicine*, 19th edition, Churchill Livingstone: 2002; 1049-55.
http://books.google.co.in/books/about/Davidson_s_principles_and_practice_of_me.html?id=5qJqAAAAMAAJ&redir_esc=y
25. Sharma N, Agarwal G, Rana AC, Bhat ZA, Kumar D. A review: Transdermal drug delivery system: A tool for novel drug delivery system. *Int. J. Drug Dev. Res.* 2011;3(3):70-84.
<http://ijddr.in/old/Documents/1/File%20no%206%20Vol%203%20Issue%203.pdf>
26. Shingade GM, Quazi A, Sabale PM, Grampurohit ND, Gadhave MV, Jadhav SL, Gaikwad DD. Review on: recent trend on transdermal drug delivery system. *J. Drug Deliv. Ther.* 2012; 2(1):66-75.
<http://jddtonline.info/index.php/jddt/article/download/74/46>
27. Shivaraj A, Selvam RP, Mani TT, Sivakumar T. Design and evaluation of transdermal drug delivery of ketotifen fumarate. *Int. J. Pharm. Biomed. Res.* 2010;1(2):42-7.
www.pharmscidirect.com/Docs/IJPBR-2010-02-08.pdf
28. Talegaonkar S, Tariq M, Alabood RM. Design and development of o/w nanoemulsion for the transdermal delivery of ondansetron. *Bull. Pharm. Res.* 2011;1(3):18-30.
<http://www.appconnect.in/wp-content/uploads/2012/06/ReprintBPR028.pdf>
29. Tortora GJ, Grabowski SR. *Principles of Anatomy and Physiology*, John Wiley & Sons, 1999.
<http://www.amazon.co.uk/Principles-Anatomy-Physiology-Gerard-Tortora/dp/0471366927>
30. Vishvakarama P, Agarwal S, Sharma R, Sharma S. Transdermal drug delivery system: review. *Int. J. Res. Pharm.* 2012;3(5):50-3.
http://www.irjponline.com/admin/php/uploads/1066_pdf.pdf
31. Vyas SP, Khar RK. *Controlled Drug Delivery: Concepts and Advances*, Vallabh Prakashan: New Delhi, 2012.
32. Vyas SP and Khar RK. *Targeted and controlled Drug Delivery Novel Carrier System*. CBS Publishers and Distributors: New Delhi, 2002.
33. Wiechers J. Use of chemical penetration enhancers in transdermal drug delivery-possibilities and difficulties. *Acta Pharm. Nord.* 1992;4(2):123.
<http://www.ncbi.nlm.nih.gov/pubmed/1388764>

34. Yamamoto T, Katakabe K, Akiyoshi K, Kan K, Asano T, Okumura M. Topical application of the hypoglycemic agent glibenclamide and changes in blood glucose, plasma insulin (IRI) levels and plasma concentration of glibenclamide in normal rats. *Diabetes Res. Clin. Pract.* 1990;8(1):19-22.
<http://www.ncbi.nlm.nih.gov/pubmed/2105197>
35. Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P. Preparation of silymarin proliposomes: a new way to increase oral bioavailability of silymarin in beagle dogs. *Int. J. Pharm.* 2006; 319(1-2):162-8.
<http://www.ncbi.nlm.nih.gov/pubmed/16687221>
36. Yuk SH, Lee SJ, Teruo O, Berner B, Kim SW. One way membrane for transdermal drug delivery systems. II: System optimization. *Int. J. Pharm.* 1991;77(2-3):231-7.
<http://www.sciencedirect.com/science/article/pii/037851739190321E>

